S-1/A: Panbela Therapeutics Eyes $27.8 Million in Public Offering to Advance Cancer Drug Development

Sentiment:

S-1/A Filing 25 January 2024 12:22 PM

📋All filings for Panbela Therapeutics, INC

Panbela Therapeutics is undertaking a best efforts public offering to raise up to $27.8 million for the clinical development of its cancer treatment candidates and for general corporate purposes.

Delay expectedOpening of clinical sites in the US and the rest of the world has been slower than originally anticipated, due in part to resource fatigue in the medical community.The Company expects all countries and sites to be open by in early 2024.

Capital raisePanbela Therapeutics is conducting a best efforts public offering of common stock and warrants.The offering includes up to 8,000,000 shares of common stock, Class E and F warrants to purchase common stock, and pre-funded warrants.The assumed combined public offering price is $3.77 per share and accompanying warrants, based on the January 23, 2024, Nasdaq Capital Market closing price.The company intends to use the net proceeds, estimated to be up to $27.8 million, for the clinical development of ivospemin and eflornithine, working capital, and general corporate purposes, including potential debt repayment.

Worse than expectedThe company's auditors have expressed substantial doubt regarding its ability to continue as a going concern.The company is not in compliance with Nasdaq listing rules.The company has a history of negative operating cash flow and has incurred significant losses since inception.

Summary

Panbela Therapeutics is conducting a best efforts public offering of common stock and warrants.
The offering includes up to 8,000,000 shares of common stock, Class E and F warrants to purchase common stock, and pre-funded warrants.
The assumed combined public offering price is $3.77 per share and accompanying warrants, based on the January 23, 2024, Nasdaq Capital Market closing price.
The company intends to use the net proceeds, estimated to be up to $27.8 million, for the clinical development of ivospemin and eflornithine, working capital, and general corporate purposes, including potential debt repayment.
Panbela is seeking to raise capital to continue its operations and execute its business plan, including completing clinical trials and pursuing regulatory approvals.
The offering is scheduled to terminate on February 15, 2024, unless completed sooner or terminated earlier by the company.
Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering.

Sentiment

Score: 4

Explanation: The document is primarily focused on a capital raise due to financial difficulties and Nasdaq compliance issues. While there are positive aspects related to clinical trials and drug development, the overall tone is cautiously optimistic due to the company's financial situation.

Positives

The offering will provide Panbela with additional capital to advance its clinical development programs.
The company has multiple ongoing clinical trials for its lead drug candidates.
Panbela has received Fast Track and Orphan Drug designations for its drug candidates, which could expedite the regulatory review process.
The company has a licensing agreement with the University of Florida Research Foundation for ivospemin.
The company has a licensing agreement with the Arizona Board of Regents of the University of Arizona for Flynpovi.

Negatives

Panbela has a history of negative operating cash flow and has incurred significant losses since inception.
The company's auditors have expressed substantial doubt regarding its ability to continue as a going concern.
The company is subject to the risk of delisting from Nasdaq.
The company is dependent on third parties for the manufacture of its product candidates.
The company faces intense competition from other pharmaceutical and biotechnology companies.

Risks

The company may be unable to obtain the additional capital required to execute its business plan.
Clinical trials are expensive and time-consuming, and their outcome is highly uncertain.
The company's product candidates may not receive regulatory approval.
The company may be subject to product liability claims.
The company may be exposed to infringement or misappropriation claims by third parties.
The company may be delisted from Nasdaq, which would harm the liquidity of its stock and its ability to raise capital.

Future Outlook

The company expects to continue to incur substantial losses and negative cash flows as it continues to pursue research and development activities and commercialize its product candidates.

Industry Context

The pharmaceutical and biotechnology industries are highly competitive and characterized by rapid and significant technological change. Panbela faces intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies.

Comparison to Industry Standards

The document does not provide enough information to make a detailed comparison to industry standards.
To make a comparison, we would need to know more about the specific clinical trial results, the target market, and the pricing strategy.
Without this information, it is difficult to assess how Panbela's results compare to those of its competitors.

Stakeholder Impact

Shareholders will experience dilution as a result of the public offering.
Employees' job security is dependent on the company's ability to raise capital and achieve its business objectives.
Patients may benefit from the development of new cancer treatments.
Suppliers and creditors may be impacted by the company's financial condition.

Next Steps

Complete the public offering.
Continue clinical development of ivospemin and eflornithine.
Seek regulatory approvals for product candidates.
Regain compliance with Nasdaq listing requirements.
Complete enrollment in ASPIRE global clinical trial by the first quarter of 2025.
Interim data analysis based on overall survival should be available by the middle of 2024.

Key Dates

Date	Description
September 2011	Sun BioPharma, Inc. was originally incorporated.
August 2015	FDA accepted Investigational New Drug (IND) application for ivospemin.
January 2016	Commencement of Phase I clinical trial of ivospemin.
September 2017	Completion of Phase I clinical trial of ivospemin.
2018	Began enrolling patients in Phase Ia/Ib study of ivospemin.
December 2020	Completed enrollment in Phase Ia/Ib study of ivospemin.
December 2, 2020	Company changed its name to Panbela Therapeutics, Inc.
January 2022	Initiation of ASPIRE clinical trial for pancreatic cancer.
June 15, 2022	Panbela acquired Cancer Prevention Pharmaceuticals, Inc. (CPP).
January 13, 2023	Completed a 1-for-40 reverse stock split.
April 2023	Regained North American rights to develop and commercialize Flynpovi in patients with FAP.
June 1, 2023	Effected a reverse stock split at a ratio of one-for-thirty (1:30) shares of the Companys common stock
July 4, 2023	Termination of the licensing agreement between CPP and One-Two Therapeutics Assets Limited effective
July 17, 2023	Divested certain rights, titles and interests in its eflornithine pediatric neuroblastoma program.
November 28, 2023	Received staff determination letter from Nasdaq regarding delisting.
December 19, 2023	Stockholders approved the issuance of the underlying shares of common stock at a special meeting
December 20, 2023	A registration statement on Form S-1 (File No. 333-275733) was declared effective by the SEC
December 21, 2023	Entered into warrant exercise inducement offer letters with certain holders of existing warrants
January 18, 2024	Completed a 1-for-20 reverse stock split.
January 22, 2024	Received notice from Nasdaq indicating non-compliance with Minimum Float Requirement.
January 23, 2024	Date of information regarding outstanding securities.
January 25, 2024	Announced that the ASPIRE trial had exceeded 50% enrollment.
February 15, 2024	Termination date of the public offering, unless completed sooner or terminated earlier.

Keywords

public offering, Panbela Therapeutics, ivospemin, eflornithine, warrants, clinical development, cancer, PBLA, Roth Capital Partners, Flynpovi

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.